home / stock / mdgef / mdgef quote
Last: | $2.43 |
---|---|
Change Percent: | 0.0% |
Open: | $2.43 |
Close: | $2.43 |
High: | $2.43 |
Low: | $2.43 |
Volume: | 500 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.43 | $2.43 | $2.43 | $2.43 | $2.43 | 500 | 03-29-2024 |
$2.43 | $2.43 | $2.43 | $2.43 | $2.43 | 500 | 03-28-2024 |
$2.76 | $2.84 | $2.76 | $2.84 | $2.76 | 200 | 03-25-2024 |
$2.53 | $2.72 | $2.53 | $2.72 | $2.53 | 200 | 03-22-2024 |
$2.27 | $2.11 | $2.27 | $2.27 | $2.11 | 200 | 03-21-2024 |
$1.76 | $1.76 | $1.76 | $1.76 | $1.76 | 500 | 03-18-2024 |
$1.93 | $1.93 | $1.93 | $1.93 | $1.93 | 2,000 | 03-15-2024 |
$1.5 | $1.5 | $1.5 | $1.5 | $1.5 | 125 | 12-28-2023 |
$1.55 | $1.55 | $1.55 | $1.55 | $1.55 | 100 | 12-27-2023 |
$1.51 | $0 | $1.51 | $0 | $0 | 50 | 12-21-2023 |
$1.51 | $1.51 | $1.51 | $1.51 | $1.51 | 250 | 12-18-2023 |
$1.55 | $0 | $1.55 | $0 | $0 | 2 | 12-15-2023 |
$1.55 | $1.55 | $1.55 | $1.55 | $1.55 | 100 | 12-12-2023 |
$1.55 | $0 | $1.55 | $0 | $0 | 10 | 11-15-2023 |
$1.55 | $1.56 | $1.55 | $1.56 | $1.55 | 12,500 | 10-31-2023 |
$1.978 | $0 | $1.978 | $0 | $0 | 47 | 10-30-2023 |
$1.978 | $0 | $1.978 | $0 | $0 | 50 | 09-20-2023 |
$1.978 | $1.978 | $1.978 | $1.978 | $1.978 | 1,219 | 09-05-2023 |
$1.86 | $1.86 | $1.86 | $1.86 | $1.86 | 3,000 | 08-28-2023 |
$2 | $0 | $2 | $0 | $0 | 20 | 08-14-2023 |
News, Short Squeeze, Breakout and More Instantly...
Planegg/Martinsried, July 23, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the presentation of two posters...
Planegg/Martinsried, July 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued...
Planegg/Martinsried, June 27, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today provides a detailed overview of its lead ...